Drug Trial Radar · NCT02710409
A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older
Last checked: Nov 20, 2026Latest source record: Sep 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,664
Actual
Start
Jan 2016
Primary completion
Jun 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- Jiangsu Province Centers for Disease Control and PreventionResearch network
- Sponsor type
- Research network
- Collaborators
- Jiangsu Jindike Biotechnology Co., Ltd.
- First posted
- Mar 16, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Influenza is an acute respiratory disease caused by influenza viruses. There are three types of the virus including A, B and C. Both type A and type B viruses can cause acute febrile respiratory tract infection, characterized by sudden fever, headache, muscle pain, cough, sore throat, nasal congestion and general malaise. The main transmission of influenza is through those highly contagious aerosol droplets containing influenza virus passed from infected people to susceptible population. Each year in the fall and winter infection of influenza is widespread in various age groups, with high incidence rate. Although influenza is generally a self-limiting disease, but in children, the elderly (especially those above 65 years old and those with chronic heart, lung, kidney, liver, blood or metabolic diseases such as diabetes or other certain diseases) and those with poor immunity function, influenza can easily lead to serious flu complications such as pneumonia, resulting in severe increase of morbidity and mortality. In order to evaluate safety and immunogenicity of a quadrivalent influenza vaccine produced by Jiangsu Jindike Biotechnology Co., Ltd. a phase III clinical trial is planned to conduct in healthy Chinese subjects aged 3 years and older.
Conditions
- Influenza
Interventions
Quadrivalent influenza vaccineBiological
0.5 ml/vial, one dose, intramuscular injection on day 0
Trivalent influenza vaccine ABiological
0.5 ml/vial, one dose, intramuscular injection on day 0
Trivalent influenza vaccine BBiological
0.5 ml/vial, one dose, intramuscular injection on day 0
Primary outcomes
What the sponsor says the trial is designed to measure.
- the 95% confidence interval (CI) lower limit for the seroconversion against each corresponding flu strain after vaccination is≥40% in subjects aged 3-59 years and≥30% in subjects aged ≥60 years separatelyTime frame: 28 days after vaccination
- incidence of solicited adverse reactions after vaccinationTime frame: 0-7 days after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guanyun County Center for Disease Control and Prevention
Lianyungang, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.